Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Risk of Thyroid Tumors One of the most concerning long-term risks associated with Ozempic is the potential for thyroid tumors, including medullary thyroid carcinoma (MTC)
Novo Nordisk may have first-mover advantage in the oral space, with oral Wegovy (obesity) and Rybelsus (T2D, launched 2019), but orforglipron is expected to outperform these on-market semaglutide options for a number of reasons: superior HbA1c reduction and weight loss
According to the available timelines, the phase 3 clinical trial is expected to conclude in early 2026 with potential FDA approval in 2027
However, it requires multiple daily doses (typically 5002000 mg split across the day), and many patients experience gastrointestinal side effects including nausea, diarrhea, and abdominal discomfort that can limit adherence
Their effectiveness in the long run requires their combination with the following: Healthy eating habits Regular physical activity Ongoing medical supervision The weight loss from GLP-1 drugs must be slow and sustainable rather than quick and erratic
